Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: A random number generator includes an input receiving unit configured to receive an input for designating a probability distribution of random numbers, a model generation unit configured to generate, based on the probability distribution, an Ising model using n binary variables (n is an integer equal to or greater than 2) each of which is assigned to a respective one of n subintervals obtained by dividing a numerical range of random numbers, an annealing result acquisition unit configured to acquire values of the n binary variables, the values being an execution result of quantum annealing for the Ising model, and a random number output unit configured to output, as a random number, a value included in the subinterval assigned to the binary variable whose value, which has been obtained as the execution result, is equal to a predetermined value.

Abstract: A steering device includes: a steering shaft; a transmitting mechanism configured to transmit the rotation of the steering shaft to a steered wheel; a power cylinder; a rotary valve configured to selectively supply a hydraulic fluid to the pair of the fluid chambers in accordance with the rotation of the steering shaft; and an electric motor configured to provide a rotation force through a speed reduction device to the steering shaft, the steering shaft including a first shaft connected to the steering wheel, and a second shaft connected to the first shaft, and configured to output the rotation force inputted from the first shaft, to the transmitting mechanism side, and the electric motor being connected through the speed reduction device to the second shaft.

Abstract: A learning device, for constructing a learning model for generating a prior acceleration command value for controlling a control target in advance of the time a load on a boiler used for thermal power generation changes, includes: a learner configured to generate the learning model by mechanically learning, as learning data, a data set including a power generation command value for the thermal power generation and the prior acceleration command value which have been used in a previous operation of the boiler.

Abstract: It is aimed to provide a terminal fitting and a chain terminal capable of maintaining connection reliability to a mating terminal. A terminal fitting (45) is provided with a box portion 46, into which a mating terminal 18 is inserted from front, a base portion (47) fixed in the box portion (46), a contact portion (48) arranged forward of the base portion (47) and configured to electrically contact the mating terminal (18) being inserted into the box portion (46), and a spring portion (49) provided to link the base portion (46) and the contact portion (48) and support the contact portion (48) displaceably in an insertion direction (R) of the mating terminal (18). The spring portion (49) is shaped such that a plurality of plate portions (49A) elongated in a direction intersecting the insertion direction (R) are folded and linked while being spaced apart in the insertion direction (R).

Abstract: A method of catalytic hydrogenation and reduction in which a reactive substrate and a hydrogen source are brought into contact in the presence of a platinum-group metal-supported catalyst to run the reactive substrate through catalytic hydrogenation and reduction; the ion exchanger is made of a continuous skeleton phase and a continuous hole phase; the thickness of the continuous skeleton is in the range of 1-100 ?m; the average diameter of the continuous holes is in the range of 1-1000 ?m; the total pore volume is in the range of 0.5-50 mL/g; the ion exchange capacity per unit weight in a dry state is in the range of 1-9 mg eq/g; and the ion exchanger is a non-particulate, weakly basic, organic porous ion exchanger where an ion exchange group is distributed in the ion exchanger.

Abstract: A support shaft capable of supporting a wound body with a long sheet wound therearound includes a first projection located at a proximal end of an outer peripheral part, and a second projection located at a distal end of the outer peripheral part. A core body of the wound body includes a one-end-side first recess part located at one end of an inner peripheral part, an other-end-side firsts recess part located at an other end of the inner peripheral part, and a second recess part located to extend from the one end to the other end. In a state where the core body is mounted on an outer periphery of the support shaft, the first projection engages the one-end-side first recess part or the other-end-side first recess part.

Abstract: It is aimed to enable a terminal fitting to be easily removed from a circuit board. A board connector (10) is provided with a terminal fitting (30) and a housing (20) in which the terminal fitting (30) is mounted, and fixed to a circuit board (12). The terminal fitting (30) includes a support receiving portion (32) to be supported by the housing (20), a connecting portion (34) to be connected to the circuit board (12), and a resiliently deformable resilient portion (33) provided between the support receiving portion (32) and the connecting portion (34). The connecting portion (34) is pressed against the circuit board (12) based on a restoring force of the resiliently deformed resilient portion (33).

Abstract: It is aimed to provide a combination terminal capable of saving assembly time by preventing an increase in the number of components at the time of assembly. A combination terminal is provided with a plurality of terminals (10A, 10B, 10C) to be stacked on each other. Each of the plurality of terminals (10A, 10B, 10C) includes a plate-like base portion (11), a plate-like guided portion (12) projecting from the base portion (11) and a locking portion (13) formed on the guided portion (12). Further, out of the terminals adjacent in a stacking direction, one (10A, 10C) of the terminals includes a guide portion (14L) to be arranged along the guided portion (12U) of the other terminal (10A, 10B, 10C) and a resiliently deformable resilient locking portion (27L) to be locked to the locking portion (13U) of the other terminal (10A, 10B, 10C).

Abstract: The present invention enables assembling by hand work. This combination terminal is provided with: a first terminal fitting (11) that has a first substrate part (12); and a second terminal fitting (41) that has a second substrate part (42) to be stacked on the first substrate part (12) and is assembled to the first terminal fitting (11) by being shifted in a direction crossing a stacking direction. An elastically deformable first elastic lock piece (22) is formed in the first terminal fitting (11), a second lock part (46) that locks the first terminal fitting (11) and the second terminal fitting (41) in an assembled state by engaging with the first elastic lock piece (22) is formed in the second terminal fitting (41), and a first protection part (28) that prevents interference of foreign matter with the first elastic lock piece (22) is formed integrally with the first terminal fitting (11).

Abstract: Provided is an ion exchanger which is composed of a polymer chain represented by general formula (1) (wherein R1 represents an alkyl group of 4 to 22 carbon atoms which may be substituted; or a benzyl group which may be substituted with an alkyl group of 1 to 6 carbon atoms which may be substituted, a halogen atom, an alkoxy group of 1 to 6 carbon atoms which may be substituted, an amino group which may be substituted, a cyano group, or a nitro group; R2 and R3 each independently represent an alkyl group of 1 to 4 carbon atoms; L represents a linker site; and “Polymer” represents a polymer chain).

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: In a platinum group metal supported catalyst column, a platinum group metal supported catalyst is a catalyst in which at least one of platinum group metal nanoparticles, platinum group metal ions, and platinum group metal complex ions is supported on an ion exchanger, wherein the exchanger is composed of a continuous skeleton phase and a continuous pore phase, the thickness of the continuous skeleton is 1-100 ?m, the average diameter of the continuous pore is 1-1000 ?m, the total pore volume is 0.5-50 mL/g, the ion exchange capacity per weight in a dry state is 1-9 mg equivalent/g, and the ion exchanger is non-particulate organic porous ion exchanger in which the ion exchange groups are distributed in the ion exchanger, the amount of platinum group metal nanoparticles, etc., supported is 0.004-20 wt % in a dry state, and a platinum group metal scavenger is provided at the backward stage catalyst.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: A platinum group metal ion-supported catalyst in which platinum group metal ions or platinum group metal complex ions are supported on a non-particulate organic porous ion exchanger, wherein the non-particulate organic porous ion exchanger is formed of a continuous framework phase and a continuous pore phase; has a thickness of a continuous framework of 1 to 100 ?m, an average diameter of continuous pores of 1 to 1000 ?m, and a total pore volume of 0.5 to 50 ml/g; has an ion exchange capacity per weight in a dry state of 1 to 9 mg equivalent/g; and has ion exchange groups wherein the ion exchange groups are uniformly distributed in the organic porous ion exchanger.

Abstract: A waste treatment system, includes: at least one reformer for hydrolyzing waste; a microbial reactor for microbially degrading a reformed material containing at least a solid of the waste hydrolyzed by the at least one reformer; a microbial reaction detection device for detecting a state of degradation of the reformed material in the microbial reactor; and an adjustment device for adjusting amount and timing of supply of the reformed material to the microbial reactor, based on a detected value of the microbial reaction detection device.

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6?-(phenyl)-2H-(1,2?-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.